Merus to Present at Upcoming Investor Conferences

GlobeNewswire

02-25

Merus logo 300dpi_.jpg

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics^®, Triclonics^® and ADClonics^®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET

Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.

Multiclonics^®, Biclonics^®, Triclonics^® and ADClonics^® are registered trademarks of Merus N.V.

CONTACT: Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
Assoc. Director IR/Corp Comms
617-230-4165
k.farren@merus.nl

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514998440"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514998440\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514998440?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2514998440","market":"us","top_or_hot":-1,"title":"Merus to Present at Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/lWxyeYbezvGt2MXBoBrfPw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/9f6bf6d9505c9f7ac97feceef1f44405\" title=\"Merus logo 300dpi_.jpg\" vspace=\"5\"/>\n<p>UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- <u>Merus N.V.</u> (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics<sup>®</sup>, Triclonics<sup>®</sup> and ADClonics<sup>®</sup>), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:</p>\n<ul type=\"disc\">\n<li>TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET<br/></li>\n</ul>\n<ul type=\"disc\">\n<li>Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET<br/></li>\n</ul>\n<p>The webcasts of the presentations will be contemporaneously available on the <u>Investors page</u> of the Company's website. The archived presentations will also be available there for a limited time after the event.</p>\n<p><strong><strong>About Merus</strong></strong><br/><u>Merus</u> is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as <u>Multiclonics</u><sup>®</sup>. Multiclonics<sup>®</sup> are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit <u>Merus’ website</u> and <u>LinkedIn</u>.<br/></p>\n<p>Multiclonics<sup>®</sup>, Biclonics<sup>®</sup>, Triclonics<sup>®</sup> and ADClonics<sup>®</sup> are registered trademarks of Merus N.V.</p>\n<pre>CONTACT: Investor and Media Inquiries:\nSherri Spear\nMerus N.V.\nSVP Investor Relations and Strategic Communications\n617-821-3246\ns.spear@merus.nl\n\nKathleen Farren\nMerus N.V.\nAssoc. Director IR/Corp Comms\n617-230-4165\nk.farren@merus.nl</pre>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merus to Present at Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerus to Present at Upcoming Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-02-25 21:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/lWxyeYbezvGt2MXBoBrfPw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/9f6bf6d9505c9f7ac97feceef1f44405\" title=\"Merus logo 300dpi_.jpg\" vspace=\"5\"/>\n<p>UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- <u>Merus N.V.</u> (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics<sup>®</sup>, Triclonics<sup>®</sup> and ADClonics<sup>®</sup>), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:</p>\n<ul type=\"disc\">\n<li>TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET<br/></li>\n</ul>\n<ul type=\"disc\">\n<li>Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET<br/></li>\n</ul>\n<p>The webcasts of the presentations will be contemporaneously available on the <u>Investors page</u> of the Company's website. The archived presentations will also be available there for a limited time after the event.</p>\n<p><strong><strong>About Merus</strong></strong><br/><u>Merus</u> is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as <u>Multiclonics</u><sup>®</sup>. Multiclonics<sup>®</sup> are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit <u>Merus’ website</u> and <u>LinkedIn</u>.<br/></p>\n<p>Multiclonics<sup>®</sup>, Biclonics<sup>®</sup>, Triclonics<sup>®</sup> and ADClonics<sup>®</sup> are registered trademarks of Merus N.V.</p>\n<pre>CONTACT: Investor and Media Inquiries:\nSherri Spear\nMerus N.V.\nSVP Investor Relations and Strategic Communications\n617-821-3246\ns.spear@merus.nl\n\nKathleen Farren\nMerus N.V.\nAssoc. Director IR/Corp Comms\n617-230-4165\nk.farren@merus.nl</pre>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/merus-present-upcoming-investor-conferences-130000039.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/merus-present-upcoming-investor-conferences-130000039.html","article_id":"2514998440","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514998440","pubTimestamp":1740488400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025  -- Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates , today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:. TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET. Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET. The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.About MerusMerus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clini","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MRUS":"Merus B.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Merus将出席即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRUS":0.9},"content_text":"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:\n\nTD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET\n\n\nLeerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET\n\nThe webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.\nAbout MerusMerus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.\nMulticlonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.\nCONTACT: Investor and Media Inquiries:\nSherri Spear\nMerus N.V.\nSVP Investor Relations and Strategic Communications\n617-821-3246\ns.spear@merus.nl\n\nKathleen Farren\nMerus N.V.\nAssoc. Director IR/Corp Comms\n617-230-4165\nk.farren@merus.nl","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}